FDA agreed on trial design for Privosegtor in optic neuritis
FDA approved the design of registration trials for the neuroprotector Privosegtor for the treatment of optic neuritis. Learn how the drug can change neuro-ophthalmology and what prospects the SPA agreement opens.
